About SynHelix
SynHelix is a Healthcare company based in Evry-courcouronnes (France) founded in 2019 by Ahmed Said and Irina Gbalou, and was acquired by Univercells in January 2022. It operates as an enzyme-based DNA synthesis technology is developed for large-scale production. Its chief executive is Irina Gbalou. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Instruments and Genomics. Its competitors include Twist Bioscience, Nuclera Nucleics, Ansa Biotechnologies, Nutcracker Therapeutics and DNA Script and 5 more; 10 of its 10 listed competitors have raised funding.
Company details
SynHelix was founded in 2019 in Evry Courcouronnes, France, within the biotechnology sector. An enzyme-based DNA synthesis solution is provided by the company, enabling gigaprep-scale production. This technology supports applications including cell and gene therapies, personalized diagnostics, and DNA vaccines. Operations focus on advancing DNA manufacturing processes for research and therapeutic uses.
- Headquarters Evry-courcouronnes, France
- Founders Ahmed Said, Irina Gbalou
- Stage Acquired
- SectorsHealthcare
- Website synhelix.com
- Social LinkedIn X
- Acquired by Univercells (Jan 2022)
- Investors
- Acquired byUnivercells
(Jan 2022)
Investors in SynHelix
SynHelix has secured backing from 1 investor. Prominent investors backing the company include Univercells.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Biomanufacturing technologies are supplied for biopharma antibody and vaccine production. | 2013 | univercells.com | Charleroi, Belgium |
Investor details for SynHelix
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of SynHelix
2 people are tracked at SynHelix (2 in leadership).
| Name | Role | Group |
|---|---|---|
Ahmed Said | Co-Founder & CTO | Leadership |
Irina Gbalou | Co-Founder & CEO | Leadership |
Complete people profiles for SynHelix
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of SynHelix
2 dated milestones of SynHelix across 3 years, from founding to its latest funding, stage changes and deals.
- Founded SynHelix is founded.
- Exit Acquired by Univercells.
Competitors of SynHelix
SynHelix has 10 listed competitors in our database, 10 of them funded. They include Twist Bioscience, Nuclera Nucleics, Ansa Biotechnologies, Nutcracker Therapeutics and DNA Script, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| twistbioscience.com | 2013 | San Francisco, United States | $245.81M | 919 | Synthetic DNA is synthesized via a semiconductor-based platform. | |
| nuclera.com | 2013 | Cambridge, United Kingdom | $164.2M | 134 | Desktop bioprinter for genes and proteins production is developed. | |
| ansabio.com | 2017 | Berkeley, United States | $175.5M | 253 | DNA synthesis technology using enzymes is provided. | |
| nutcrackerx.com | 2018 | Emeryville, United States | $227.04M | – | mRNA therapeutics are developed via proprietary biochip platforms. | |
| dnascript.com | 2014 | Paris, France | $301.69M | – | Benchtop DNA printers for nucleic acid synthesis are developed. | |
| sensible.bio | 2021 | Wilmington, United States | $4.33M | – | Developer of mRNA technology for therapeutics and vaccines | |
| synplechem.com | 2016 | Zurich, Switzerland | $10,200 | – | Automated chemical synthesizers are developed using reagent capsules. | |
| oriciro.com | 2018 | Tokyo, Japan | $10.87M | – | Technologies for DNA synthesis and amplification are developed. | |
| mesabiotech.com | 2009 | San Diego, United States | $26.8M | 131 | Point-of-care molecular diagnostic kits are developed and supplied. | |
| cambriangenomics.com | 2011 | San Francisco, United States | $11.23M | – | Developers of technology for laser printing DNA |
Detailed competitors of SynHelix
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
10 companies that operate in the same segment as SynHelix (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 562 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Synhelix
Complete news archive for SynHelix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about SynHelix
SynHelix was founded in 2019.
SynHelix is headquartered in Evry-courcouronnes, France. It is registered at Evry-courcouronnes, Essonne, France.
Irina Gbalou is the current CEO of SynHelix. They have also founded this company.
SynHelix was founded in 2019 in Evry Courcouronnes, France, within the biotechnology sector. An enzyme-based DNA synthesis solution is provided by the company, enabling gigaprep-scale production. This technology supports applications including cell and gene therapies, personalized diagnostics, and DNA vaccines. Operations focus on advancing DNA manufacturing processes for research and therapeutic uses.
SynHelix's top competitors include Nuclera Nucleics, Twist Bioscience and Ansa Biotechnologies.
SynHelix has 1 investor. Key investors include Univercells.
Yes. SynHelix was acquired by Univercells in January 2022.